MANNITOL 5% IN PLASTIC CONTAINER Drug Patent Profile
✉ Email this page to a colleague
When do Mannitol 5% In Plastic Container patents expire, and what generic alternatives are available?
Mannitol 5% In Plastic Container is a drug marketed by B Braun and Icu Medical Inc and is included in two NDAs.
The generic ingredient in MANNITOL 5% IN PLASTIC CONTAINER is mannitol. There are eighteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the mannitol profile page.
Summary for MANNITOL 5% IN PLASTIC CONTAINER
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 164 |
Clinical Trials: | 222 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MANNITOL 5% IN PLASTIC CONTAINER at DailyMed |
Recent Clinical Trials for MANNITOL 5% IN PLASTIC CONTAINER
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Ecole Polytechnique Fédérale de Lausanne | Early Phase 1 |
Centre Hospitalier Universitaire Vaudois | Early Phase 1 |
University Hospital Inselspital, Berne | Early Phase 1 |
Pharmacology for MANNITOL 5% IN PLASTIC CONTAINER
Drug Class | Osmotic Diuretic |
Mechanism of Action | Osmotic Activity |
Physiological Effect | Increased Diuresis |
Anatomical Therapeutic Chemical (ATC) Classes for MANNITOL 5% IN PLASTIC CONTAINER
US Patents and Regulatory Information for MANNITOL 5% IN PLASTIC CONTAINER
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
B Braun | MANNITOL 5% IN PLASTIC CONTAINER | mannitol | INJECTABLE;INJECTION | 020006-001 | Jul 26, 1993 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Icu Medical Inc | MANNITOL 5% IN PLASTIC CONTAINER | mannitol | INJECTABLE;INJECTION | 019603-001 | Jan 8, 1987 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for MANNITOL 5% IN PLASTIC CONTAINER
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Pharmaxis Europe Limited | Bronchitol | mannitol | EMEA/H/C/001252 Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. |
Authorised | no | no | no | 2012-04-13 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |